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AbstractNeuromyelitis optica spectrum disorders (NMOSD) are central nervous system 
inflammatory disorders. Recently, autoimmunity against aquaporin-4 (AQP4) water channel is identified to be the underlying immunopathogenetic mechanism of the majority of NMOSD patients. This is evidenced by the detection of IgG 
autoantibodies against aquaporin-4 (AQP4-IgG) in the serum of ~75%-80% of 
typical neuromyelitis optica patients. Detection of AQP4-IgG is highly specific for NMOSD, facilitates diagnosis of NMOSD and their distinction from classical 
multiple sclerosis. Besides its diagnostic value, AQP4-IgG is likely directly pathogenic in NMOSD. This review focuses on the immunopathological effects of 
AQP4-IgG in NMOSD.
IntroductionNeuromyelitis optica (NMO) and NMO spectrum disorders 
(NMOSD) are central nervous system inflammatory demyelinating disorders (CNS IDD) characterized by monophasic or relapsing optic neuritis (ON), acute myelitis (AM) and less commonly encephalitis [1]. NMO-IgG, an autoantibody detected in serum 
of 73% of NMO but not in classical multiple sclerosis (CMS) 
patients [2]. The autoantigen targeted by NMO-IgG is aquaporin-4 
(AQP4), the major CNS water channel protein which is abundantly 
expressed in foot processes of astrocytes [3]. The discovery 
of these IgG autoantibodies against aquaporin-4 (AQP4-IgG) 
detected in the serum of ~75% of NMO patients has clarified 
that NMOSD seropositive for AQP4-IgG are not CMS, but an autoimmune disorder affecting CNS astrocytes (astrocytopathy). 
NMOSD patients seropositive for AQP4-IgG have underlying 
autoimmunity against CNS astrocytic AQP4. A small proportion 
of patients with typical NMO (relapsing ON and extensive AM without brain involvement suggestive of CMS) and some with 
restricted forms such as relapsing extensive myelitis without 
ON are seronegative for AQP4-IgG. The immunopathogenesis of 
these patients are uncertain. A proportion of these patients (~20-
25%) are seropositive for IgG autoantibodies against myelin oligodendrocyte glycoprotein (MOG-IgG). The pathogenesis of 
MOG-IgG positive patients await clarification from further studies, especially histopathological studies of affected CNS tissues.In NMOSD, patients typically have monophasic or relapsing 
severe AM and ON, with relatively less frequent brain involvement 
especially in the early phase, and CSF OCB are infrequent [1]. NMO 
patients typically have severe neurological disability after attacks 
of extensive myelitis, severe ON and brainstem encephalitis 
[4], no secondary progression and worse clinical outcome 
than CMS patients [1,5]. Pathologically, spinal cord tissues of 
NMO patients exhibit necrosis in both gray and white matter, 
infiltrating leucocytes (macrophages, polymorphonuclear cells [neutrophils, eosinophils], and lymphocytes), activated microglia, 
demyelination, axonal loss, thickened hyalinized vessel walls with deposits of IgM, IgG and complement activation products in a vasculocentric rim and rosette pattern. These hyalinized vessel walls with deposits of immunoglobulins and complement activation products in the characteristic vasculocentric rim and rosette pattern is not observed in lesions of CMS patients.
Clinical usefulness of AQP4-IgG
Distinction of NMOSD from CMS can be difficult especially in the early stage [5]. In addition, brain involvement in NMO 
is increasingly recognized, and NMO patients with MRI brain 
lesions fulfilling criteria for CMS are reported [6]. Early diagnosis of NMOSD is important as disability in NMOSD is 
relapse-related [1], hence relapse prevention is the key in treatment. Importantly, commonly used disease modifying 
drugs for relapsing MS including β-interferon, fingolimod and natalizumab may be ineffective or even harmful in NMOSD by 
precipitating development of extensive hemispheric lesions [7]. Immunosuppression by azathioprine/mycophenolate mofetil and 
corticosteroids or B-cell depletion therapy (e.g. rituximab) should be initiated early in NMOSD to prevent relapses and disabilities 
[8]. Detection of AQP4-IgG greatly facilitates early diagnosis and prompt treatment of NMOSD. 
Immunopathologic effects of AQP4-IgG
AQP4-IgG is predominantly of IgG1 subclass, and binds to AQP4 
abundantly expressed as transmembrane protein in astrocytic end feet processes at glial limitans abutting capillaries in pia, subpia and subependyma, and less abundantly in ependymal cells 
[3]. AQP4 has six transmembrane regions and three extracellular 
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loops with intracytoplasmic amino and carboxyl terminals. AQP4 
exists as heterotetramers formed by the M1 and M23 isoforms (the 2 major isoforms). CNS AQP4 play important roles in 
functional integrity of blood-brain barrier (BBB) and CNS water homeostasis, regulating water transport across the interfaces 
between blood and brain, and between brain and CSF [9]. Using sera from 32 NMOSD patients with high serum concentrations of 
AQP4-IgG, Iorio et al. [10] showed that AQP4-IgG from NMOSD 
patients bind to extracellular loops, monomers, tetramers and 
high order orthogonal arrays of particles (OAP) of AQP4, and 
disease-specific epitopes reside in extracellular loop C more 
than in loop A or E. Importantly, AQP4-IgG bind most avidly to 
membrane AQP4 epitopes formed by loop interations within 
tetramers and intermolecular interations within OAP [10].
AQP4-IgG are likely directly pathogenic in NMOSD. IgG from 
serum of AQP4-IgG positive NMO patients bound to extracellular 
region of membrane AQP4 of transfected HEK293 cells and triggeredI. Internalization and endolysosomal degradation of bound 
AQP4, andII. Complement activation with deposition of terminal lytic 
membrane attack complex, C9neo, causing cell lysis [11]. 
QP4-IgG induced necrosis of cultured astrocytes in a 
complement-dependent manner. AQP4-IgG binding to extracellular 
domains of AQP4 have isoform-specific outcomes, M1 isoform is completely internalized while M23 isoform aggregates into larger 
OAP via cross-linking and resist internalization. The Fc portion of 
the AQP4-IgG bound to these OAP triggers complement activation 
followed by astrocyte cytotoxicity, infiltration of lymphocytes and granulocytes (neutrophils, eosinophils) leading to intense neuro-
inflammation, and tissue necrosis [12]. An in-vitro study that 
cultured rat astrocytes exposed to IgG from AQP4-IgG positive 
NMOSD patients developed into a reactive and inflammatory 
phenotype with increased expression of lipocalin-2 and a wide 
spectrum of cytokines, chemokines and stress response factors [13]. The same group also reported that stimulation of astrocytes 
by AQP4-IgG led to NFκB-dependent inflammatory response which is one of the earliest events in NMOSD pathogenesis.In-vivo studies revealed that passive transfer of IgG from 
AQP4-IgG positive NMOSD patients into laboratory animals with 
experimental autoimmune encephalomyelitis (EAE) induced by immunization with myelin proteins or adoptive transfer of myelin 
protein-reactive T lymphocytes enhanced CNS inflammation and worsened EAE score. Immunohistochemistry revealed loss of 
AQP4 and astrocytes in CNS lesions of the animals, mimicking pathologies of NMOSD patients. Intracerebral injection of IgG from 
AQP4-IgG positive patients together with human complements 
into mouse brains induced NMO-like lesions with loss of AQP4 
and astrocytes without preexisting inflammation. This study supports the important role of complement activation in neuro-
inflammation and CNS tissue necrosis/damage in NMOSD. Rats 
immunized with complete Freud’s adjuvant (CFA) only without 
myelin protein followed by passive transfer of IgG from AQP4-IgG 
positive NMOSD patients developed NMO-like lesions in spinal cord. 
Colleagues and I studied the pathogenic role of AQP4-IgG in the absence of complement activation by passive transfer of IgG isolated from sera of NMO patients into mice (human IgG 
cannot activate mouse complements). Breakdown of BBB was 
induced before transfer of human IgG by subcutaneous CFA and 
intraperitoneal pertussis toxin (PTx). We observed that mice 
treated with IgG from AQP4-IgG positive NMOSD patients had 
areas of AQP4 loss in spinal cord while mice treated with IgG from 
AQP4-IgG negative NMOSD patients and IgG from healthy subjects did not. All mice had no clinical features of encephalomyelitis 
and no inflammatory cell infiltration, demyelination or loss 
of glial fibrillary acidic protein (GFAP) immunoreactivity. In 
addition, mice treated with IgG from AQP4-IgG positive NMOSD 
patients showed evidences of astrocytic activation with marked proliferation of foot processes. These suggest:I. CFA and PTx alone lead to BBB breakdown,II. AQP4-IgG from NMOSD patient’s induced asymptomatic 
AQP4 loss and astrocytic activation without inflammatory 
cell infiltration, demyelination or astrocytic cytoxicity in the absence of complement activation, andIII. AQP4-IgG can activate astrocytes in the absence of 
complement activation [14].A recent animal study showed that chronic infusion of IgG from 
AQP4-IgG positive NMOSD patients to CSF of rats results in motor impairment of the animal associated with astrocyte alteration 
characterized by loss of AQP4, myelin basic protein, axons and 
reduced glutamate uptake but no immune cell infiltration, microglial activation or complement activation.
AQP4 expression is markedly reduced in cord lesions of NMOSD patients but preserved or increased in cord lesions of CMS 
patients [15]. Recent histopathological studies further confirm that NMOSD have distinct pathologies from CMS. Although different pathologies are observed in different sites of lesions, 
AQP4 loss and astrocytic injury or cytotoxicity (loss) are the key pathologies in cord and brain lesions of NMOSD whereas normal 
AQP4 level and gliosis are observed in brain and cord lesions of 
CMS patients [15,16]. Loss of AQP4 is always observed in CNS lesions of NMOSD patients, whereas loss of astrocyte, complement activation and necrosis are variable. Histopathological studies of brainstem lesions at the dorsal medulla (area postrema without 
intact BBB) from a small number of NMOSD patients revealed loss 
of AQP4, prominent astrocytic activation, lymphocytic infiltration, microglial reactivation, some complement activation products but 
no obvious axonal or neuronal injury. It is proposed that AQP4-
IgG binding to astrocytic AQP4 at this site is followed by rapid 
internalization of antigen-antibody complex, possibly explained 
by predominantly AQP4 M1 expressed in this site. The astrocytes 
reacted with inflammatory response leading to inflammatory cell 
infiltration without obvious demyelination, axonal or neuronal injury [17].
Conclusion
Current evidence suggests AQP4-IgG binding to astrocytic 
AQP4 are the initial step in neuroinflammation of NMOSD. 
AQP4-IgG in peripheral blood become accessible to CNS AQP4 
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at sites without intact BBB (such as the area postrema) or 
during inflammatory condition such as infection during which 
proinflammatory cytokines in circulation lead to breakdown of 
BBB. The astrocytic activation triggered upon binding of AQP4-
IgG to AQP4 M1 and internalization of antigen-antibody complex 
release proinflammatory cytokines and chemokines leading to 
inflammatory cell infiltration. Other immune cells are activated with secretion of complements which will be activated especially 
at sites with high level of AQP4 M23 and hence OAP.
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